Table 2.
Changes in glycemic control by glimepiride and vildagliptin
| Baseline | Glimepiride | Vildagliptin | P † | |
|---|---|---|---|---|
| Dose (mg/day) | NA | 1.45 ± 0.34 | 80.4 ± 9.2 | NA |
| Symptomatic hypoglycemia, n (12 weeks) | NA | 0.75 ± 1.24 | 0.44 ± 1.26 | 0.381 |
| SMBG at hypoglycemic episodes (mmol/L) | NA | 4.3 ± 0.7 | 3.8 ± 0.1 | 0.464 |
| FPG (mmol/L) | 9.6 ± 1.4 | 8.2 ± 1.8‡ | 7.7 ± 2.4‡ | 0.496 |
| HbA1c, % (mmol/mol) | 8.4 ± 0.9 (68.0 ± 5.6) | 6.7 ± 0.4§ (50.0 ± 2.5) | 6.6 ± 0.9§ (49.0 ± 5.6) | 0.799 |
| 1,5‐AG (μmol/L) | 34.8 ± 23.8 | 74.0 ± 56.6§ | 85.4 ± 42.2§ | 0.569 |
| HOMA‐B | 25.8 ± 14.4 | 53.0 ± 30.5§ | 61.5 ± 39.6§ | 0.499 |
| CGMS data | ||||
| Log(MBG) (mmol/L) | 1.03 ± 0.11 | 0.93 ± 0.09‡ | 0.91 ± 0.12‡ | 0.547 |
| Log(MAGE) (mmol/L) | 0.75 ± 0.17 | 0.64 ± 0.18‡ | 0.62 ± 0.19‡ | 0.768 |
| Log(SD) (mmol/L) | 0.38 ± 0.15 | 0.29 ± 0.15‡ | 0.25 ± 0.14‡ | 0.456 |
| CONGA‐6 (mmol/L) | 67.8 ± 31.5 | 54.3 ± 23.3 | 46.9 ± 23.2‡ | 0.373 |
| Log(M100) | 1.41 ± 0.44 | 0.99 ± 0.46§ | 0.87 ± 0.51§ | 0.493 |
| AUC180 (mmol/L∙min) | 6,103 ± 6,206 | 1,913 ± 2,566§ | 2,137 ± 4,129§ | 0.855 |
| Duration of glucose <4.4 mmol/L (min) | 8.14 ± 16.72 | 68.75 ± 184.81‡ | 86.56 ± 190.56‡ | 0.752 |
Data are presented as mean ± standard deviation. †Student's t‐test or Mann–Whitney test between glimepiride and vildagliptin. ‡ P < 0.05 vs baseline by paired t‐test or Wilcoxon matched‐pairs signed rank test. § P < 0.01 vs baseline by paired t‐test or Wilcoxon matched‐pairs signed rank test. 1,5‐AG, 1,5‐anhydroglucitol; AUC180, area under the curve for glucose above 180 mg/dL; CONGA‐6, continuous overlapping net glycemic action calculated with 6‐h time intervals; FPG, fasting plasma glucose; HOMA‐B, homeostasis model assessment for β‐cell function; M100, weighted average of glucose values; MAGE, mean amplitude glycemic excursion; MBG, mean blood glucose; NA, not applicable; SD, standard deviation; SMBG, self‐measured blood glucose.